T
Tatsuya Yamashita
Researcher at Kanazawa University
Publications - 221
Citations - 9903
Tatsuya Yamashita is an academic researcher from Kanazawa University. The author has contributed to research in topics: Hepatocellular carcinoma & Internal medicine. The author has an hindex of 43, co-authored 186 publications receiving 7604 citations.
Papers
More filters
Journal ArticleDOI
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
Andrew X. Zhu,Richard S. Finn,Julien Edeline,Stéphane Cattan,Sadahisa Ogasawara,Daniel H. Palmer,Chris Verslype,Vittorina Zagonel,Laetitia Fartoux,Arndt Vogel,Debashis Sarker,Gontran Verset,Stephen L. Chan,Jennifer J. Knox,Bruno Daniele,Andrea L. Webber,Scot Ebbinghaus,Junshui Ma,Abby B. Siegel,Ann-Lii Cheng,Masatoshi Kudo,Angela Tatiana Alistar,Jamil Asselah,Jean-Frédéric Blanc,Ivan Borbath,Timothy Cannon,Ki Chung,Allen Lee Cohn,David Cosgrove,Nevena Damjanov,Mukul Gupta,Yoshivasu Karino,Mark Karwal,Andreas Kaubisch,Robin Kate Kelley,Jena-Luc Van Laethem,Timothy Larson,James Lee,Daneng Li,Atisha Manhas,Gulam Abbas Manji,Kazushi Numata,Benjamin M. Parsons,Andrew Scott Paulson,Carmine Pinto,Robert A. Ramirez,Suresh Ratnam,Magnus Rizell,Olivier Rosmorduc,Yvonne Sada,Yutaka Sasaki,Per I Stal,Simone I. Strasser,Joerg Trojan,Gina M. Vaccaro,Hans Van Vlierberghe,Alan Weiss,Karl-Heinz Weiss,Tatsuya Yamashita +58 more
TL;DR: Pembrolizumab was effective and tolerable in patients with advanced hepatocellular carcinoma who had previously been treated with sorafenib and is undergoing further assessment in two phase 3, randomised trials as a second-line treatment.
Journal ArticleDOI
JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan
Masatoshi Kudo,Osamu Matsui,Namiki Izumi,Hiroko Iijima,Masumi Kadoya,Yasuharu Imai,Takuji Okusaka,Shiro Miyayama,Kaoru Tsuchiya,Kazuomi Ueshima,Atsushi Hiraoka,Masafumi Ikeda,Sadahisa Ogasawara,Tatsuya Yamashita,Tetsuya Minami,Koichiro Yamakado +15 more
TL;DR: The Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma proposed by the Japan Society of Hepatology was updated in June 2014 at a consensus meeting of the Liver Cancer Study Group of Japan.
Journal ArticleDOI
A Liver-Derived Secretory Protein, Selenoprotein P, Causes Insulin Resistance
Hirofumi Misu,Toshinari Takamura,Hiroaki Takayama,Hiroto Hayashi,Naoto Matsuzawa-Nagata,Seiichiro Kurita,Kazuhide Ishikura,Hitoshi Ando,Yumie Takeshita,Tsuguhito Ota,Masaru Sakurai,Tatsuya Yamashita,Eishiro Mizukoshi,Taro Yamashita,Masao Honda,Ken-ichi Miyamoto,Tetsuya Kubota,Naoto Kubota,Takashi Kadowaki,Han Jong Kim,Inkyu Lee,Yasuhiko Minokoshi,Yoshiro Saito,Kazuhiko Takahashi,Yoshihiro Yamada,Nobuyuki Takakura,Shuichi Kaneko +26 more
TL;DR: It is demonstrated that selenoprotein P (SeP), a liver-derived secretory protein, causes insulin resistance and suggested that SeP may be a therapeutic target for type 2 diabetes.
Journal ArticleDOI
Hepatic ISG Expression Is Associated With Genetic Variation in Interleukin 28B and the Outcome of IFN Therapy for Chronic Hepatitis C
Masao Honda,Akito Sakai,Tatsuya Yamashita,Yasunari Nakamoto,Eishiro Mizukoshi,Yoshio Sakai,Taro Yamashita,Mikiko Nakamura,Takayoshi Shirasaki,Katsuhisa Horimoto,Yasuhito Tanaka,Katsushi Tokunaga,Masashi Mizokami,Shuichi Kaneko +13 more
TL;DR: The expression of hepatic ISGs is strongly associated with treatment response and genetic variation of IL28B, and the differential role of host and viral factors as predicting factors may also be present.
Journal ArticleDOI
Hepatocellular Carcinoma: Signal Intensity at Gadoxetic Acid–enhanced MR Imaging—Correlation with Molecular Transporters and Histopathologic Features
Azusa Kitao,Yoh Zen,Osamu Matsui,Toshifumi Gabata,Satoshi Kobayashi,Wataru Koda,Kazuto Kozaka,Norihide Yoneda,Tatsuya Yamashita,Shuichi Kaneko,Yasuni Nakanuma +10 more
TL;DR: The enhancement ratio of HCCs in the hepatobiliary phase of gadoxetic acid-enhanced MR imaging positively correlated with expression levels of OATP8 and MRP3, indicating that gadoxetics acid is taken up by OATp8 and excreted by MRp3.